BioSpace News Archive

There is a growing demand for treatments that offer tissue regeneration. Since pulsed electromagnetic field (PEMF) external devices product segment is projected for aggressive growth in the bone growth stimulators market, healthcare providers are becoming increasingly aware about its advantages.

Gynecological diseases represent a collective term given to different medical conditions specific to the female reproductive system.

According to latest market report on the non-invasive prenatal testing market for the historical period of 2017–2021 and forecast period of 2022–2030, increase in maternal age and increasing demand for early and non-invasive fetal testing procedures are anticipated to drive the global non-invasive prenatal testing market.

The adoption of electrically powered/myoelectric technology is predicted to grow at an aggressive rate during the forecast period.

Intellia Therapeutics, Inc., a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, announced the appointment of Muna Bhanji, R.Ph., to its board of directors.

Kiniksa Pharmaceuticals, Ltd. announced that it will host a conference call and live webcast on Tuesday, May 3, 2022, at 8:30 a.m. Eastern Time to report its first quarter 2022 financial results and corporate activities.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces the presentation of three novel cell programming approaches at the American Society of Gene & Cell Therapy being held May 16-19, 2022.

Codexis, Inc. announced two poster presentations highlighting three of the Company’s gene therapy programs using directed evolution to potentially improve treatment options for Hemophilia A and lysosomal storage diseases at the American Society of Gene and Cell Therapy 25th Annual Meeting, taking place from May 16 to May 19, 2022, in Washington, D.C. and virtually.

Editas Medicine, Inc. announced that four abstracts have been accepted for presentation, including three oral presentations, at the 25th Annual Meeting of the American Society of Gene and Cell Therapy being held in Washington, D.C., and virtually, May 16 – 19, 2022.

Sana Biotechnology, Inc. announced that five abstracts covering preclinical data from its hypoimmune and fusogen platforms were accepted for either oral or poster presentation at the American Society of Gene and Cell Therapy 25th Annual Meeting taking place May 16-19, 2022 in Washington, D.C.